High temperature for solid loads

Aseptic manufacturing depends on preserving the required state of every material until its point of use. Yet reusable parts, pre-sterilized components, bulk closures, tools and auxiliary materials enter the process from different conditions, through different routes and with different vulnerabilities.

Treatment alone does not secure the flow: unloading, transport, storage, manipulation and connection create critical interfaces where control can be lost. As manufacturing architectures become more closed, integrated and automated, aseptic transfer becomes a system-level responsibility.

RTU manufacturing carries more value - and more responsibility.

Ready-to-use cartridge manufacturers are taking on a critical role in biopharmaceutical supply chains. By supplying cartridges already washed, depyrogenated, siliconized, assembled, packaged and sterile, they enable pharma companies to outsource container preparation and the associated validation burden.

Insulin production increasingly relies on high-throughput syringes and cartridge filling lines, with cartridges serving reusable and disposable delivery pens. At these output levels, filling capacity alone does not determine production performance.

Closures and reusable filling-line parts must be washed, sterilized, handled and delivered to the filling area at the required pace and under controlled aseptic conditions. If these upstream activities are managed as separate, disconnected operations, they can become a bottleneck while increasing equipment, transfers, manual handling and operating costs.

Vaccine manufacturing places exceptional demands on fill-finish operations, where product sterility depends on the controlled preparation and transfer of every component entering the aseptic filling area.

Sterile vials, stoppers and product-contact machine parts must be available in step with the filling line and introduced without contamination or particle exposure. Multiple preparation systems, intermediate containers and manual transfers increase process complexity, footprint and critical interfaces. Dependence on ready-to-use components can also limit sourcing and campaign flexibility.

Albumin is a heat-sensitive biological product. Once prepared, purified, formulated and stabilized, it is sterile-filtered and aseptically filled into final glass vials or bottles. Because it is not subjected to conventional terminal sterilization at 121°C, the filled and sealed containers undergo validated pasteurization at 60°C for at least 10 hours to support viral inactivation while preserving protein stability and product quality.

Albumin pasteurization is traditionally performed in water-bath systems. Although effective for heat transfer, this established approach requires very large quantities of process water, increasing utility consumption, wastewater generation and operating costs across a long and production-critical treatment

Radiopharmaceutical production combines pharmaceutical contamination control with the radiological protection of operators and the surrounding environment. The exact route varies with the radionuclide, formulation, product stability, container and intended diagnostic or therapeutic use. Some products are sterilizing-filtered and aseptically filled; others can be filled, closed and terminally sterilized. At the same time, reusable product-contact parts require controlled preparation, while radioactive wastewater cannot automatically enter the conventional drain.

Sterile powder manufacturing presents one of the most demanding combinations of aseptic processing and high-containment production. Reusable containers, machine parts and thermosensitive materials must each follow dedicated preparation pathways before entering the filling environment, while uninterrupted production campaigns require a sufficient number of sterile containers to be available before filling can even begin. The challenge therefore extends well beyond aseptic filling itself: manufacturers must coordinate washing, depyrogenation, sterilization, material bio-decontamination, protected transfers and containment into a single validated manufacturing workflow that preserves both product sterility and operator safety.

High-potent sterile manufacturing is one of the fastest-growing pharmaceutical sectors, driven by oncology biologics, antibody-drug conjugates (ADCs), peptides and other highly active compounds. While aseptic filling remains essential, manufacturers must simultaneously protect product sterility, operators and the surrounding environment. As occupational exposure limits decrease to the ng/m³ range, every reusable machine component leaving the filling isolator becomes a potential contamination source.

Ready-to-fill vial manufacturers supply pharmaceutical companies with primary containers that are already washed, depyrogenated, packaged and sterile, transferring container preparation and part of its qualification burden upstream. Growing demand for injectable biologics is increasing production volumes while making conventional sterilization routes more difficult to sustain. Steam may exceed the thermal limits of some packaging materials, while EtO introduces toxic-residue concerns and extended degassing times.

Drug-device combination products can bring together a thermosensitive drug, a complex delivery system and a protective package within a single sterilization challenge. For blistered prefilled syringes, the process must reach external surfaces, recessed areas and partially enclosed geometries without exposing the filled product to damaging temperatures. Sterilant penetration through the Tyvek® layer must therefore be demonstrated, together with microbial effectiveness inside the blister and around critical syringe components.

Hyaluronic acid pre-filled syringes combine a thermally sensitive formulation with a pressure-sensitive container-closure system. Product performance depends on the molecular weight and rheological behaviour of the formulation, while moist heat progressively reduces viscosity as exposure continues. At the same time, heating increases the internal pressure of the filled syringe through liquid expansion and vapour pressure, potentially causing plunger movement, leakage or loss of container integrity.

The rapid growth of biologics, nanoparticle-based medicines and Advanced Therapy Medicinal Products (ATMPs) is redefining the relationship between pharmaceutical formulations and primary packaging.
Interactions between proteins such as insulin, nanoparticles and container surfaces are well-recognised phenomena that can influence product stability, efficacy and patient safety. As these therapies become increasingly sensitive, material compatibility can no longer be considered an intrinsic property of the container alone.